| Adhesion and Invasion Assay Procedure Using Caco-2 Cells for Listeria monocytogenes
|
|
Author:
Date:
2017-05-05
[Abstract] Listeria monocytogenes is an important Gram-positive foodborne pathogen that is a particular problem in ready-to-eat food. It has an ability to survive in harsh conditions like refrigeration temperatures and high salt concentrations and is known to cross intestinal, placental and blood-brain barriers. Several cancerous cell lines like cervical, liver, dendritic, intestinal and macrophages have been used to study in vitro propagation and survival of listeria in human cells. Human intestinal epithelial cells have been used to study how listeria crosses the intestinal barrier ...
[摘要] 单核细胞增生利斯特氏菌是一种重要的革兰氏阳性食源性病原体，是即食食品中的一个特殊问题。它具有在诸如制冷温度和高盐浓度的恶劣条件下生存的能力，并且已知可以穿过肠，胎盘和血脑屏障。已经使用了诸如子宫颈，肝脏，树突状细胞，肠和巨噬细胞的几种癌细胞系来研究人细胞中李斯特菌的体外扩增和存活。人肠上皮细胞已被用于研究李斯特菌如何穿过肠屏障并引起感染。本文中的方案描述了生长Caco-2细胞的过程，维持细胞并将其用于粘附和侵袭测定。在粘附测定期间，将细胞与李斯特菌孵育30分钟，但是在侵袭测定中，细胞生长在感染后的几个时间点被停止以监测细胞中李斯特菌的生长和存活率。
背景 ...
|
|
|
| Evaluation of Angiogenesis Inhibitors Using the HUVEC Fibrin Bead Sprouting Assay
|
|
Author:
Date:
2016-10-05
[Abstract] Angiogenesis, the growth of new blood vessels from pre-existing vessels, is a critical process that occurs during normal development and tumor formation. Targeting tumor angiogenesis by blocking the activity of vascular endothelial growth factor (VEGF) has demonstrated some clinical benefit; nevertheless there is a great need to target additional angiogenic pathways. We have found that the human umbilical vein endothelial cell (HUVEC) fibrin bead sprouting assay (FBA) is a robust and predictive in vitro assay to evaluate the activity of angiogenesis inhibitors. Here, we describe an ...
[摘要] 血管发生，来自预先存在的血管的新血管的生长是在正常发育和肿瘤形成期间发生的关键过程。通过阻断血管内皮生长因子（VEGF）的活性靶向肿瘤血管生成已经证明了一些临床益处;然而，非常需要靶向额外的血管生成途径。我们已经发现，人脐静脉内皮细胞（HUVEC）纤维蛋白珠发芽测定（FBA）是评估血管生成抑制剂的活性的稳健的和预测性的体外测定。在这里，我们描述了用于评估血管生成的生物抑制剂和关键终点的自动定量的优化的FBA方案。
[背景] 血管发生，新血管的生长从先前存在的血管，是在伤口愈合和正常发育期间发生的生理过程。血管生成是一个复杂和高度调节的过程，涉及内皮细胞增殖，分化，迁移，基质粘附和细胞间的信号的紧密协调。血管发生也严重参与肿瘤发展和转移。事实上，通过阻断血管内皮生长因子（VEGF）的活性靶向肿瘤血管生成已经证明了临床益处。由于肿瘤最终对VEGF靶向治疗产生抗性，因此非常需要靶向额外的血管生成途径。我们已经发现人脐静脉内皮细胞（HUVEC）纤维蛋白珠发芽测定（FBA）（Nakatsu等人，2007; Nakatsu和Hughes，2008; ...
|
|
|